跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2020/12/029783
CTRI/2020/12/029783招募中不适用

Therapy with nintedanib –Does it improve outcome in patients of Covid-19 pneumonia if given early?

PRATIMA SINGH1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2020年12月14日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
招募中
发起方
PRATIMA SINGH
入组人数
30
试验地点
1
主要终点
Improvement in CT thorax findings(CT severity score).
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

NINTEDANIB HAS PROVEN ANTIFIBROTIC EFFECTS AND ITS USE IN IDIOPATHIC PULMONARY FIBROSIS IS WELL KNOWN. COVID 19 ALSO CAUSES LUNG FIBROSIS AND OXYGEN DEPENDENCY. EARLY INTERVENTION WITH ANTIFIBROTICS HAS BENEFITS BUT NOTHING IS CONCLUSIVELY PROVEN TILL DATE. SO THE NEED TO EVALUATE EARLY THERAPY WITH NINTEDANIB IN COVID 19 FIBROSIS.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)（—）
性别
All

入选标准

  • •All cases of covid 19 pneumonia detected as COVID positive within ≤ 30 days or with history and CT suggestive of covid 19 .
  • •CT-severity score ≥15 and CORADS-4/5/6.

排除标准

  • •Patients having other interstitial lung diseases.
  • •Patient having CKD or creatinine clearance <30 and CLD with deranged LFT will be excluded. -Not fulfilling the criteria for study -Not giving consent for study.

结局指标

主要结局

Improvement in CT thorax findings(CT severity score).

时间窗: 6WEEKS 12WEEKS.

次要结局

  • improvement in CT-severity score(6 WEEKS, 12 WEEKS)

研究者

发起方
PRATIMA SINGH
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Effects of nintedanib in idiopathic pulmonary fibrosis - analysis on long term prognosis and predictive factorsIdiopathic pulmonary fibrosis
JPRN-UMIN000021036ational Hospital Organization Tokyo Medical Center, Department of Respiratory Medicine100
招募中
不适用
intedanib therapy will improve management in covid 19 fibrosis if given early or not.
CTRI/2020/12/029783PRATIMA SINGH
进行中（未招募）
4 期
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaNovel Coronavirus-induced Lung Fibrosis
NCT04856111Post Graduate Institute of Medical Education and Research, Chandigarh48
已完成
2 期
Efficacy of nintedanib on severe COVID-19 pneumonia.
JPRN-jRCTs051200036memura Yutaka30
终止
不适用
Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung DiseaseMyopathy, InflammatoryInterstitial Lung Disease
NCT05335278McGill University Health Centre/Research Institute of the McGill University Health Centre11